Introduction
============

Atherosclerotic disease (AD) is a systemic disease that affects all arterial beds and can present with multiple clinical manifestations according to the end organ supplied, including the heart in coronary artery disease (CAD), and the lower extremities in peripheral artery disease (PAD). Risk factors for AD include male sex, advanced age, cigarette smoking, hypertension, diabetes, and hyperlipidaemia.[@b1-vhrm-8-349]

Atherosclerotic disease is the leading cause of death worldwide and in Saudi Arabia.[@b2-vhrm-8-349],[@b3-vhrm-8-349] In Saudi Arabia, both CAD and PAD are a major public health problem, with an overall prevalence of 5.5%[@b4-vhrm-8-349] and 11.7% amongst people aged 45 years and older,[@b5-vhrm-8-349] respectively. PAD is a marker of advanced atherosclerosis and is associated with an elevated risk of cardiovascular mortality and morbidity; with a four-fold increased risk of myocardial infarction[@b6-vhrm-8-349] and a two to three-fold increased risk of stroke.[@b7-vhrm-8-349] Furthermore, the risk of cardiovascular mortality and morbidity in patients with PAD is comparable to that in patients with CAD.[@b8-vhrm-8-349]

Reducing the adverse cardiovascular outcomes of atherosclerosis through risk factor identification and modification has been an active area of research over the past few decades. As a result, several large scale randomized clinical trials[@b9-vhrm-8-349]--[@b11-vhrm-8-349] and observational studies[@b12-vhrm-8-349],[@b13-vhrm-8-349] have shown intensive risk reduction therapy to be very effective and critical in reducing adverse cardiovascular outcomes in patients with AD, with many expert international committees recommending the use of risk reduction practices as summarized in [Table 1](#t1-vhrm-8-349){ref-type="table"}.[@b14-vhrm-8-349]--[@b17-vhrm-8-349] However, the level of awareness of this information and the implementation of risk factor reduction therapy amongst all physicians is felt to be low, and has been shown to be suboptimal amongst general practitioners, internal medicine specialists, cardiologists, and vascular surgeons in the United States, Canada, and Europe.[@b18-vhrm-8-349]--[@b24-vhrm-8-349]

A small pilot study carried out at a university hospital in Saudi Arabia[@b25-vhrm-8-349] showed that there is a knowledge and action gap among physicians with respect to risk factor modification in patients with PAD. However, the knowledge and attitudes of physicians across Saudi Arabia towards risk reduction therapy for patients with AD are not known. Therefore, this study was performed to assess the knowledge of the recommended target levels for blood pressure, blood glucose, and low density lipoprotein-cholesterol (LDL-C), as well as to explore physicians' knowledge and attitudes towards risk reduction therapy in patients with AD. We also examined differences among physicians in the management of these factors in patients with PAD compared to patients with CAD in Saudi Arabia.

Materials and methods
=====================

A self-administered questionnaire was mailed to all family physicians, general internists, cardiologists, and vascular surgeons working at different hospitals in four provinces in Saudi Arabia: central -- Riyadh and Qassim; east -- Dammam, Khobar, Qatif, Jubail, Hafof, and Hafer Albatin; west -- Jeddah, Makkah, and Madinah; and south -- Abha, Jizan, and Najran. The hospitals were randomly selected and included public, teaching, and private hospitals between March 1, 2009 and February 28, 2010. The questionnaire was based on a previously published and validated questionnaire.[@b25-vhrm-8-349] The questionnaire was anonymous and physicians provided consent prior to participation. This study was approved by the King Khalid University Hospital ethics review board, Riyadh, Saudi Arabia.

The survey consisted of multiple choice questions. Participant demographic information was collected, including age, sex, specialty, board certification status, and years of experience. All questions were asked with regards to patients with PAD and CAD. The questions aimed to: (1) assess participant knowledge of AD risk factors, including target levels of blood pressure, LDL-C, and blood glucose; and (2) assess participant attitudes towards AD risk reduction therapies. Participants were asked about their attitudes towards: patient counseling of cardiovascular risk reduction; comfort with recommending and instituting risk reduction therapy (smoking cessation, antiplatelet medications, statins, angiotensin converting enzyme \[ACE\] inhibitors, and antihypertensive medications); factors that influence adequate risk reduction therapy delivery; proportion of patients with PAD or CAD who have their vascular risk factors evaluated systematically; and self-assessment of PAD or CAD risk reduction knowledge.

All survey results were expressed as percentages. The number of respondents who completed each question was used as the denominator for proportions of responses. The prespecified subgroups for comparison analysis of responses to PAD or CAD scenarios were by specialty type -- family physicians, general internists, cardiologists, and vascular surgeons. Chi-square tests were used to compare proportions between different subgroups. All *P*-values reported were two-tailed, and values of *P* = 0.05 were considered significant.

Results
=======

529 of the 897 surveyed physicians completed the survey, representing a response rate of 59%. Family physicians, general internists, cardiologists, and vascular surgeons represented 20.2%, 41.4%, 28%, and 10.4% of the surveyed physicians, respectively. The results are depicted in [Tables 2](#t2-vhrm-8-349){ref-type="table"}--[5](#t5-vhrm-8-349){ref-type="table"}.

Physicians' characteristics
---------------------------

Two-thirds of participating physicians were board-certified in their specialties and had been practicing for more than 10 years. Most of the respondents were working in nonacademic institutions ([Table 2](#t2-vhrm-8-349){ref-type="table"}).

Physicians' knowledge and attitude
----------------------------------

The knowledge of the surveyed participants about the recommended targets of LDL-C, blood pressure, and blood glucose was low for both CAD and PAD, and there was no statistical difference between the knowledge for both entities by specialty ([Table 3](#t3-vhrm-8-349){ref-type="table"}). Only 38% knew that an ACE inhibitor can be initiated as an anti-atherosclerotic therapy in PAD patients irrespective of blood pressure status, compared to 46% for CAD (*P* \< 0.05). Although surveyed cardiologists still showed a knowledge gap in the use of ACE inhibitors for patients with AD, their positive response was statistically higher compared with other specialties (*P* \< 0.05). The majority of surveyed physicians indicated that their self-assessment of risk reduction in PAD and CAD (78% and 77%, respectively) was average to above average. One-third of surveyed family physicians indicated that their self-assessment of risk reduction knowledge in CAD and PAD (31% and 30%, respectively) was below average.

Although surveyed physicians' attitudes towards routine risk factor evaluation and associated patient counseling showed a very optimal response, the attitude towards patient assessment for risk factors was suboptimal ([Table 4](#t4-vhrm-8-349){ref-type="table"}). Apart from routine initiation of antiplatelet therapy (98% for CAD and 96% for PAD), the attitude towards routine initiation and/ or modification of other risk reduction therapy was very poor, especially for the initiation of ACE inhibitors (52% for CAD and 34% for PAD). The surveyed cardiologists were observed to be more likely to initiate different risk reduction therapies when compared to other specialists (*P* \< 0.05); however, on the whole, it was still suboptimal. On the other hand, vascular surgeons appeared to have the highest threshold for initiating these therapies; it was, however, only statistically significant for low rates of ACE inhibitor initiation (*P* \< 0.05).

Barriers to the delivery of risk reduction therapy
--------------------------------------------------

The barriers to the delivery of adequate risk reduction therapy are shown in [Table 5](#t5-vhrm-8-349){ref-type="table"}.

Discussion
==========

In this study we found that even though the majority of surveyed physicians evaluate and counsel patients with AD (CAD and PAD) for their risk factors, knowledge and action remain suboptimal, with clear gaps in knowledge identified. The majority of surveyed physicians rated their knowledge about risk reduction as average or above average. However, clear deficiencies in knowledge were identified including: (1) the recommended target levels for blood pressure, blood glucose, and LDL-C; and (2) that ACE inhibitor medications can be used in patients with atherosclerosis irrespective of blood pressure status to reduce atherosclerotic complications and cardiovascular death, with less than half of participants aware of this fact. Furthermore, initiation of all components of risk reduction therapy except antiplatelet medication was poor. The action gap was most prominent amongst family physicians and vascular surgeons when compared to other specialties.

Our findings could be explained by the absence of national or locally adapted guidelines in managing patients with AD, self-audit of practice, and focused continuing medical education programs on risk reduction therapy. Furthermore, suboptimal use of ACE inhibitors could be explained by the fact that the supporting evidence for the use of ACE inhibitors in patients with PAD to reduce the risk of adverse cardiovascular events is not Level A evidence, and is also dependent on the presence of symptoms (ie, class 2a recommendation for symptomatic patients with PAD, and Class 2b recommendation for asymptomatic patients).[@b14-vhrm-8-349]

Knowledge and action gaps in managing risk factors in patients with AD have also been shown amongst physicians in the United Kingdom, the United States, and Canada.[@b18-vhrm-8-349],[@b22-vhrm-8-349],[@b23-vhrm-8-349],[@b26-vhrm-8-349],[@b27-vhrm-8-349] Cassar et al[@b22-vhrm-8-349] showed that over a quarter of UK vascular surgeons did not screen for diabetes or measure blood pressure in patients with PAD. For instance, only 34% of vascular surgeons treated patients with claudication if cholesterol levels were greater than 5.5 mmol/L. McDermott et al[@b18-vhrm-8-349] showed that only 45.5% of internal medicine physicians prescribe antiplatelet medications to patients with PAD compared with 52.5% of vascular surgeons, and only 16.8% of vascular surgeons were aware of the large effect of cholesterol lowering on the risk of future cardiovascular events in patients with PAD compared to 43.6% of the internal medicine physicians. Furthermore, even amongst cardiologists who were surveyed there were knowledge and action gaps in dealing with atherosclerotic risk. Al-Omran et al[@b23-vhrm-8-349] showed that utilization of risk reduction pharmacotherapy and knowledge of the recommended target levels of blood glucose, blood pressure, and LDL-C levels in patients with PAD amongst Canadian vascular surgeons was suboptimal. Mukherjee et al[@b26-vhrm-8-349] showed a suboptimal use of lifestyle modifications including: smoking cessation; exercise; weight reduction and diet for lipid control; and evidence-based therapy including antiplatelet medications, ACE-inhibitors, beta-blockers, and statins, in patients undergoing peripheral vascular interventions for PAD at hospital discharge and at 6 months follow-up. The knowledge and action gaps in managing risk factors in patients with AD from previously published studies[@b18-vhrm-8-349],[@b22-vhrm-8-349]--[@b23-vhrm-8-349],[@b27-vhrm-8-349] along with our data, support the fact that there is an international trend of suboptimal use of atherosclerotic risk reduction therapies.

In the evaluation of these results, certain limitations merit emphasis. The validated questionnaire used in this study was based on the 2006 recommendations for secondary prevention.[@b16-vhrm-8-349] An update of recommendations has been released in 2011;[@b17-vhrm-8-349] however, there were no major differences in the recommendations that were used in the questionnaire for surveyed physicians. As the data represented self-reported perceptions of knowledge, they may indicate an underestimation of the true knowledge gap that exists. Lastly, the survey form did not differentiate between symptomatic and asymptomatic atherosclerotic disease with regards to the use of ACE inhibitors as a risk reduction therapy.

Conclusion
==========

In Saudi Arabia there are knowledge and action gaps with regards to AD risk reduction therapy amongst physicians, despite a considerable effort to evaluate and counsel patients for their risk factors. Given the heightened risk of cardiovascular adverse outcomes in patients with AD, and the fact that AD is the leading cause of death in Saudi Arabia,[@b3-vhrm-8-349] the results of this study have important and immediate implications. This study may be used to support a call to action for AD management and provide guidance for targeted interventions including: locally adapted clinical practice guidelines, self-audit of practice, continuing medical education programs, public awareness campaigns, the inclusion of risk reduction pharmacotherapy as a plenary topic at scientific meetings, and other educational outreach programs that aim to bring physicians' practice into agreement with current guidelines for AD risk reduction.
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###### 

Current recommendations of the American Heart Association and American College of Cardiology for risk reduction in patients with coronary artery disease compared to patients with peripheral arterial disease[@b14-vhrm-8-349],[@b16-vhrm-8-349],[@b17-vhrm-8-349]

                      Recommendation                       Class of recommendation   Level of evidence       
  ------------------- ------------------------------------ ------------------------- ------------------- --- ---
  Medications used                                                                                           
   Antiplatelet       All patients                         1                         1                   A   A
   Statin             All patients                         1                         1                   B   B
   ACE inhibitors     Symptomatic patients                 1                         1                   A   B
                      Asymptomatic patients                2a                        2a                  B   B
  Goals in managing                                                                                          
   Blood pressure     Systolic                                                                               
                       \<140 mmHg in all patients          1                         1                   A   A
                       \<130 mmHg in diabetic patients                                                       
                      Diastolic                                                                              
                       \<90 mmHg in all patients                                                             
                       \<80 mmHg in diabetic patients                                                        
  LDL-C               LDL \< 2.5 mmol/L in all patients    1                         1                   A   A
  Diabetes            HbA~1c~ \< 7% in diabetic patients   1                         1                   B   B
  Smoking             Complete cessation in all patients   1                         1                   B   B
  BMI                 18.5--24.9 kg/m^2^ in all patients   1                         1                   B   B

**Notes:** Class 1: Conditions for which there is evidence and/or general agreement that a given procedure or treatment is beneficial, useful, and effective; Class 2: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment; Class 2a: Weight of evidence/opinion is in favor of usefulness/efficacy. Level of evidence A: data derived from multiple randomized clinical trials or meta-analyses; Level of evidence B: data derived from a single randomized trial or non-randomized studies.

**Abbreviations:** AHA/ACC, American Heart Association and American College of Cardiology; CAD, coronary artery disease; PAD, peripheral artery disease; ACE, Angiotensin converting enzyme; LDL-C, low density lipoprotein-cholesterol; HbA~1c~, glycosylated hemoglobin A~1c~; BMI, body mass index.

###### 

Characteristics of physicians who completed the survey by specialty (N = 529)

                          Family physicians (N = 107)   General internists (N = 219)   Cardiologists (N = 148)   Vascular surgeons (N = 55)   All (N = 529)
  ----------------------- ----------------------------- ------------------------------ ------------------------- ---------------------------- ---------------
  Response rate, %        66                            53                             53                        85                           59
  Mean age, y, ±SD        43.2 ± 5.2                    39.7 ± 7.2                     38.8 ± 6.5                39.5 ± 4.2                   40.8 ± 5.3
  Male sex, %             69                            74                             74                        93                           75
  Board-certified, %      60                            56                             69                        58                           61
  Academic institute, %   33                            22                             22                        16                           24
  Years in practice                                                                                                                           
   \<5 years, %           19                            12                             8                         17                           13
   5--10 years, %         25                            28                             24                        15                           25
   \>10 years, %          56                            60                             68                        68                           62

**Abbreviations:** N, number; SD, standard deviation.

###### 

Knowledge of surveyed physicians of risk reduction in patients with atherosclerotic arterial diseases expressed in percentage

                                                                                                 Family physicians (N = 107)   General internists (N = 219)   Cardiologists (N = 148)   Vascular surgeons (N = 55)   All (N = 529)                       
  ---------------------------------------------------------------------------------------------- ----------------------------- ------------------------------ ------------------------- ---------------------------- --------------- ---- ---- ---- ---- ----
  Knowledge of the current recommended target of                                                                                                                                                                                                         
   LDL-C (\<2.5 mmol/L)                                                                          37                            35                             42                        39                           43              45   31   24   40   36
   Blood pressure (\<140/90 mmHg)                                                                29                            28                             33                        25                           36              31   28   28   32   28
   Blood glucose (HbA~1c~ \< 7%)                                                                 62                            59                             72                        64                           76              73   64   54   70   65
  Knowledge of the relationship between BP and ACE inhibitors in patients with atherosclerosis                                                                                                                                                           
   Not indicated in normal BP                                                                    45                            36                             27                        31                           25              19   20   31   29   29
   Initiate irrespective to BP status                                                            42                            29                             51                        41                           45              47   34   23   46   38
   Unclear about recommendations                                                                 14                            35                             22                        28                           30              34   45   46   25   33
  Self-assessment of atherosclerosis risk reduction knowledge                                                                                                                                                                                            
   Average                                                                                       31                            43                             28                        38                           17              25   29   31   25   34
   Above average                                                                                 38                            27                             50                        40                           65              56   50   57   52   44
   Below average                                                                                 31                            30                             22                        22                           18              19   21   12   23   22

**Abbreviations:** ACE, angiotensin converting enzyme; LDL-C, low density lipoprotein-cholesterol; HbA~1c~, glycosylated hemoglobin A~1c~; CAD, coronary artery disease; PAD, peripheral arterial disease; BP, blood pressure.

###### 

The attitudes of surveyed physicians towards risk reduction in patients with atherosclerotic arterial diseases expressed in percentage

                                                                                  Family physicians (N = 107)   General internists (N = 219)   Cardiologists (N = 148)   Vascular surgeons (N = 55)   All (N = 529)                          
  ------------------------------------------------------------------------------- ----------------------------- ------------------------------ ------------------------- ---------------------------- --------------- ----- ----- ----- ---- ----
  \<50%                                                                           30                            59                             31                        33                           21              27    31    27    28   36
  \>50%                                                                           56                            37                             65                        60                           75              67    69    69    66   58
  Attitude towards routine evaluation of risk factors                                                                                                                                                                                        
   L ipid profile measurement                                                     97                            91                             99                        95                           99              99    93    89    98   95
   Blood pressure measurement                                                     100                           99                             100                       100                          98              100   98    96    99   99
   Blood glucose measurement                                                      97                            94                             100                       97                           100             96    98    94    99   96
   Asking about smoking                                                           98                            97                             100                       100                          100             99    100   100   99   99
  Attitude towards routine patient counseling with regards to the importance of                                                                                                                                                              
   LDL-C reduction                                                                98                            96                             99                        96                           99              97    91    89    98   96
   Blood pressure control                                                         98                            99                             100                       100                          100             98    93    96    99   99
   Blood glucose control                                                          98                            97                             97                        97                           99              97    96    96    98   97
   Smoking cessation (advising to stop)                                           93                            94                             99                        98                           100             98    100   100   98   97
  Attitude towards routine initiating/modifying risk-reduction pharmacotherapy                                                                                                                                                               
   Statin                                                                         55                            42                             62                        57                           68              63    48    57    61   56
   ACE inhibitor                                                                  39                            23                             55                        37                           66              44    24    17    52   34
   Anti-hypertensive                                                              53                            47                             63                        61                           76              68    43    45    63   58
   Anti-platelets                                                                 97                            96                             99                        97                           100             99    93    93    98   97
   Nicotine replacement therapy                                                   36                            30                             54                        44                           57              50    38    42    50   43
   Referral to smoking cessation program                                          30                            28                             47                        41                           41              39    46    37    42   37

**Abbreviations:** ACE, angiotensin converting enzyme; LDL-C, low density lipoprotein-cholesterol; CAD, coronary artery disease; PAD, peripheral arterial disease.

###### 

Barriers to the delivery of risk reduction therapy in patients with atherosclerotic arterial disease as viewed by surveyed physicians expressed in percentage

  Barriers                                                              Family physicians (N = 107)   General internists (N = 219)   Cardiologists (N = 148)   Vascular surgeons (N = 55)   All (N = 529)                       
  --------------------------------------------------------------------- ----------------------------- ------------------------------ ------------------------- ---------------------------- --------------- ---- ---- ---- ---- ----
  Lack of knowledge of treating physicians about AD                     11                            20                             9                         9                            11              10   10   15   10   12
  Lack of AD locally adapted management guidelines                      19                            17                             14                        14                           13              17   12   10   15   15
  Absence of continuing education about risk reduction therapy for AD   30                            18                             23                        24                           21              25   12   18   22   22
  Combination of all above factors                                      40                            44                             54                        45                           55              45   66   55   53   46

**Abbreviations:** AD, atherosclerotic arterial disease; CAD, coronary artery disease; PAD, peripheral arterial disease.
